<DOC>
	<DOCNO>NCT01236027</DOCNO>
	<brief_summary>Biologic sample necessary development validation laboratory procedure ( e.g . novel biological analytical assay , explant tissue model , validation specimen collection transport ) support future infectious disease clinical study . In research study , investigator collect blood sample , vaginal swab , cervical swab , mucus/vaginal discharge , cervicovaginal lavage , vaginal cervical biopsy , necessary , use development laboratory process . The investigator obtain sample ( ) healthy HIV negative woman . Samples collect sent Magee-Womens Research Institute laboratory specimen need .</brief_summary>
	<brief_title>Specimen Collection Study Development Validation Laboratory Procedures</brief_title>
	<detailed_description />
	<criteria>Control Group ( postmenopausal ) Inclusion : 1 . Females , age great 50 year 2 . Nonpregnant 3 . Postmenopausal define menses vaginal bleeding least 1 year 4 . Agree HIV test documentation negative HIV test result within past 6 month . 5 . Free participant report clinician observe abnormal discharge vaginal symptom ( exception vaginal dryness ) day genital sample collection . 6 . Willing able provide write informed consent . 7 . Willing provide contact information receipt laboratory result , applicable . Reproductiveaged Group 1 . Females , 1845 year age 2 . Nonpregnant 3 . Agree HIV test documentation negative HIV test result within past 6 month . 4 . Free participant report clinician observe abnormal vaginal discharge current vaginal symptom day genital sample collection . 5 . Willing able provide write informed consent . 6 . Willing provide contact information receipt laboratory result , applicable . 7 . Participant meet requirement specific laboratory study need ( e.g . birth control method length use ) Control Group ( postmenopausal ) 1 . Use hormone replacement therapy , include oral , vaginal transdermal . 2 . Hysterectomy . 3 . An active urogenital infection within past 14 day , include : 1 . Vaginal infection ( symptomatic candidiasis , trichomonas vaginalis , bacterial vaginosis ) . 2 . Cervical infection ( Gonorrhea ( GC ) , Chlamydia ( CT ) mucopurulent cervicitis ( MPC ) ) . 3 . Syphilis 4 . HSV/Genital Warts 5 . Urinary Tract Infection 6 . Recent exposure partner GC , CT , trichomonas , syphilis , nongonococcal urethritis , HIV . 4 . Use systemic vaginal antibiotic antifungal 14 day prior genital sample collection . 5 . Participation microbicide vaginal product study within one month genital sample collection . 6 . Use spermicide spermicidally lubricate condom within one week prior genital sample collection . 7 . Use internal vaginal device product exception tampon within one week genital sample collection . 8 . Any condition opinion site investigator would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data otherwise interfere achieve study objective . Reproductiveaged Group 1 . Menopausal ( include natural menopause define lack menses 12 consecutive month , absence pregnancy , surgical menopause define woman ovary remove ) . 2 . Currently pregnant ( pregnant within past 90 day ) breastfeed 3 . Hysterectomy . 4 . Use diaphragm NuvaRing contraception use spermicide primary contraception . 5 . An active urogenital infection within past 14 day , include : 1 . Vaginal infection ( symptomatic candidiasis , Trichomonas vaginalis bacterial vaginosis ) . 2 . Cervical infection ( Gonorrhea ( GC ) , Chlamydia ( CT ) Mucopurulent cervicitis ( MPC ) . 3 . Syphilis 4 . HSV/Genital Warts 5 . Urinary Tract Infection 6 . Recent exposure partner GC , CT , Trichomonas , syphilis , Nongonococcal urethritis HIV . 6 . Use systemic vaginal antibiotic antifungal 14 day prior genital sample collection . 7 . Participation microbicide and/or contraceptive study within one month genital sample collection . 8 . Use spermicide spermicidally lubricate condom within one week prior genital sample collection . 9 . Use internal vaginal device product exception tampon within one week genital sample collection . 10 . Any condition opinion site investigator would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>